Kübler A, Haase T, Rheinwald M, Barth T, Mühling J
Department of Oral and Maxillofacial Surgery, University of Heidelberg, Germany.
Int J Oral Maxillofac Surg. 1998 Dec;27(6):466-9. doi: 10.1016/s0901-5027(98)80040-4.
A new therapy for the treatment of oral leukoplakia by 5-aminolevulinic acid (ALA) and photodynamic therapy (PDT) is presented. ALA, a precursor in the biosynthesis of haeme, induces the production of the endogenous photosensitizer protoporphyrin IX which can be used for PDT. Twelve patients, who had been suffering from leukoplakia of the oral mucosa for several years, were treated by ALA-mediated PDT. ALA was used as a topical photosensitizer and 20% ALA cream was applied to the leukoplakia lesion of the oral mucosa for two hours and then light activated at 630 nm, 100 mW/cm2 and 100 J/cm2. Five patients showed complete response to the treatment, four patients showed a partial response and in three patients treatment was unsuccessful. One patient with partial response was retreated, after which the lesion disappeared.
本文介绍了一种用5-氨基酮戊酸(ALA)和光动力疗法(PDT)治疗口腔白斑的新疗法。ALA是血红素生物合成的前体,可诱导内源性光敏剂原卟啉IX的产生,后者可用于PDT。12例患有口腔黏膜白斑数年的患者接受了ALA介导的PDT治疗。ALA用作局部光敏剂,将20%的ALA乳膏涂抹于口腔黏膜白斑病变处两小时,然后在630nm、100mW/cm²和100J/cm²的条件下进行光激活。5例患者对治疗完全有效,4例患者部分有效,3例患者治疗无效。1例部分有效的患者接受了再次治疗,之后病变消失。